Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15425873 | 1.00 | KMT2A (0.51) | KMT2AL3MBTL1CHRM2LMNACHRM4 | |
| SCHEMBL12902953 | 1.00 | KMT2A (0.51) | KMT2AL3MBTL1CHRM2LMNACHRM4 | |
| Bromide SCHEMBL9957539 | 0.98 | KMT2A (0.50) | KMT2AL3MBTL1CHRM2LMNACHRM4 | |
| Hydrochloric Acid SCHEMBL18063 | 0.98 | CHRM2 (0.53) | KMT2AL3MBTL1CHRM2LMNACHRM4 | |
| SCHEMBL719296 | 0.93 | CHRM2 (0.53) | L3MBTL1CHRM2CHRM4CHRM5ALDH1A1 | |
| SCHEMBL707808 | 0.93 | CHRM2 (0.53) | L3MBTL1CHRM2CHRM4CHRM5ALDH1A1 | |
| SCHEMBL19364501 | 0.93 | CHRM2 (0.53) | L3MBTL1CHRM2CHRM4CHRM5ALDH1A1 | |
| SCHEMBL29691892 | 0.93 | CHRM2 (0.53) | L3MBTL1CHRM2CHRM4CHRM5ALDH1A1 | |
| SCHEMBL16766368 | 0.93 | CHRM2 (0.53) | L3MBTL1CHRM2CHRM4CHRM5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1633577 | 0.91 | CHRM2 (0.56) | L3MBTL1CHRM2CHRM4CHRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3959213-B1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023028054-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-11439641-B2 | Pyrimidine JAK inhibitors for the treatment of skin diseases | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-13 | — | — | US | disclosed |
| WO-2022175402-A1 | QUINUCLIDINE-3-ONE DERIVATIVES | APREA THERAPEUTICS AB (SE) | 2022-08-25 | — | — | WO | disclosed |
| EP-3959213-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | Theravance Biopharma R&D IP, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-112876472-A | Process for the preparation of 9-azabicyclo [3.3.1] non-N-oxyl radicals | 南京药石科技股份有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-20200338073-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2020219640-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-0984966-B1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH AS (DK) | 2003-01-29 | — | — | EP | disclosed |
| US-6392045-B1 | 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors | NEUROSEARCH A/S (DK) | 2002-05-21 | — | — | US | disclosed |
| EP-0984966-A1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH A/S (DK) | 2000-03-15 | — | — | EP | disclosed |
| US-H1838-H | MITICIDES | FMC CORPORATION | 2000-02-01 | — | — | US | disclosed |
| WO-1998054182-A1 | 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS | NEUROSEARCH A/S (DK) | 1998-12-03 | — | — | WO | disclosed |
| US-5641786-A | Quinuclidine derivatives | LOWE III JOHN ADAMS (US) | 1997-06-24 | — | — | US | disclosed |
| US-5422354-A | Quinuclidine derivatives | PFIZER INC (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0540526-B1 | QUINUCLIDINE DERIVATIVES | PFIZER (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0540526-A1 | QUINUCLIDINE DERIVATIVES. | PFIZER (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001688-A1 | QUINUCLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439641-B2 | Pyrimidine JAK inhibitors for the treatment of skin diseases | JAK1, JAK3, JAK2 | KMT2A 1395/4885L3MBTL1 4170/4885CHRM2 4874/4885 |
| US-20200338073-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | JAK1, JAK3, JAK2 | KMT2A 1395/4885L3MBTL1 4170/4885CHRM2 4874/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | KMT2A 2421/4885L3MBTL1 316/4885CHRM2 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.